585 related articles for article (PubMed ID: 33516224)
1. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus.
Li T; Providencia R; Mu N; Yin Y; Chen M; Wang Y; Liu M; Yu L; Gu C; Ma H
Cardiovasc Diabetol; 2021 Jan; 20(1):30. PubMed ID: 33516224
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
3. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
4. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
5. Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease-A Systematic Review and Meta-Analysis.
Hu Y; Lei M; Ke G; Huang X; Peng X; Zhong L; Fu P
Front Endocrinol (Lausanne); 2020; 11():559446. PubMed ID: 33117278
[TBL] [Abstract][Full Text] [Related]
6. Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials.
Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):699-704. PubMed ID: 33549430
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
[TBL] [Abstract][Full Text] [Related]
8. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
Wang F; He Y; Zhang R; Zeng Q; Zhao X
Medicine (Baltimore); 2017 Sep; 96(36):e7638. PubMed ID: 28885325
[TBL] [Abstract][Full Text] [Related]
10. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
11. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
12. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
13. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.
Ram E; Lavee J; Tenenbaum A; Klempfner R; Fisman EZ; Maor E; Ovdat T; Amunts S; Sternik L; Peled Y
Cardiovasc Diabetol; 2019 Sep; 18(1):118. PubMed ID: 31526382
[TBL] [Abstract][Full Text] [Related]
14. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.
Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL
J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
16. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
Han Y; Xie H; Liu Y; Gao P; Yang X; Shen Z
Cardiovasc Diabetol; 2019 Jul; 18(1):96. PubMed ID: 31362743
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.
Boussageon R; Supper I; Bejan-Angoulvant T; Kellou N; Cucherat M; Boissel JP; Kassai B; Moreau A; Gueyffier F; Cornu C
PLoS Med; 2012; 9(4):e1001204. PubMed ID: 22509138
[TBL] [Abstract][Full Text] [Related]
18. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.
Griffin SJ; Leaver JK; Irving GJ
Diabetologia; 2017 Sep; 60(9):1620-1629. PubMed ID: 28770324
[TBL] [Abstract][Full Text] [Related]
19. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.
Rao AD; Kuhadiya N; Reynolds K; Fonseca VA
Diabetes Care; 2008 Aug; 31(8):1672-8. PubMed ID: 18458139
[TBL] [Abstract][Full Text] [Related]
20. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
